-
RBC Capital Upgrades Abbvie (ABBV) to Outperform, Added to Offensive Positioning List
-
Abbvie (ABBV) PT Lowered to $79 at RBC Capital
-
Pre-Open Movers 03/18: (VXRT) (APRN) (BNTX) Higher; (CZR) (BA) (ERI) Lower (more...)
-
UPDATE: RBC Capital Starts Abbvie (ABBV) at Sector Perform
-
Pre-Open Movers 01/29: (IMMR) (DPS) (KS) Higher; (CYOU) (SOHU) (ADNT) Lower (more...)
-
Trump's corporate tax holiday could spur pharma M&A
-
Pfizer boosts cancer drug roster with $14 billion Medivation deal
-
Notable Analyst Rating Changes 11/2: (MGM) (ABBV) (KEY) Upgraded; (JMEI) (SBRA) (ANET) Downgraded
-
Vertex (VRTX) Seen as Top Large-Cap Biotech Growth Idea at RBC
-
IMS Releases Gilead (GILD), AbbVie (ABBV) Weekly HCV Data
-
Pre-Open Stock Movers 03/05: (KYTH) (PCYC) (KR) Higher; (BRLI) (JOY) (ABBV) Lower (more...)
-
AbbVie (ABBV) /Pharmacyclics (PCYC) Deal Bullish for SMID Biotech and Big Drugs, Says RBC
-
Gilead (GILD) Harvoni+Sovaldi New Scripts Increased 1% Last Week
-
Gilead (GILD) Weekly Harvoni Scripts Data Shows Gains
-
Gilead (GILD) IMS Harvoni Data Delayed; Symphony Data Shows Gains in NRx
-
Notable Analyst Rating Changes 1/9: (WYNN) (BAH) (EXC) Upgraded; (NUAN) (ABBV) (NBR) Downgraded
-
Gilead Sciences (GILD) to Get Relief from CVS (CVS) Deal, Says RBC
-
IMS Reports AbbVie (ABBV) Viekira Pak Week 1 Scripts (GILD)
-
RBC Outlines What to Expect Ahead of Initial AbbVie (ABBV) Viekira Pak Scripts (GILD)
-
Gilead (GILD) Could Unleash Massive Accelerated Repurchase, Suggests RBC Capital
-
Gilead (GILD) Tanks; Analyst Comments on Express Scripts (ESRX) Viekira Pak Announcement (ABBV)
-
Gilead (GILD) Decline Tied to Johnson & Johnson (JNJ) Statements; RBC Calls Fall Buying Opportunity
-
Pre-Open Stock Movers 9/3: (ISNS) (INFI) (BTH) Higher; (END) (DGLY) (HELE) Lower (more...)
-
Infinity Pharmaceutical (INFI) Should Be Up at Least 50% Following AbbVie (ABBV) Agreement, Says RBC Capital
-
Notable Analyst Rating Changes 08/12: (FFIV) (CVC) (LKQ) Upgraded; (TSLA) (VOYA) (JNPR) Downgraded